 |
 |
 |
 |
| TECHNOLOGY PLATFORM |
 |
 |
 |
 |
 |
 |
The most promising cancer vaccine in development today
CG Therapeutics, Inc. is a biotechnology company that is developing a range of anti-hCG cancer therapy products that targets all solid tumors. CG201, the first of these products, promises to be one of the safest, most side-effect free cancer therapeutic agents ever brought to the clinic.
CG201 is a completely different cancer vaccine:
- No systemic side effects; limited to an injection site reaction similar to a flu shot
- Increased patient survival by stopping the spread and growth of tumor cells
- Improved quality of life
- Fights all solid tumor cancers
According to the World Health Organization's 2008 World Cancer Report, 25 million people in the world are cancer patients. CG Therapeutics believes it is its social responsibility to bring relief to as many of these patients as possible by bringing its therapies to market as quickly as possible at an affordable price.
The company is dedicated to continuing its research in spite of the currently difficult funding environment. Like many life science companies, the normal avenues of funding have narrowed, however, CG Therapeutics is reaching out to alternate sources. Management is committed to moving the science forward because this vaccine is simply too important to give up on. Especially now on the heels of the very promising news announced on April 28, 2009 by Dendreon Corporation, stating their cancer vaccine immunotherapy, Provenge®, "significantly improved survival" in men with metastatic prostate cancer in a Phase 3 trial. This news further galvanizes the CG Therapeutics team to continue to move its own cancer vaccine immunotherapy forward at all costs.
